Formulation Featured Articles

  1. Comparing Advanced Modality Needs, Part 1: Manufacturing 11/13/2026

    ADCs, AOCs, ATMPs, cell and gene therapies, and oligonucleotide therapeutics represent distinct but interconnected approaches to precision medicine. Let's take a closer look at their manufacturing needs.

  2. In Silico Development: What CMC Teams Can Decide Before The Lab 11/4/2026

    Formulation risk is often a timing problem rather than a technical one. Sequence-based prediction can narrow candidates, pH, and excipient choices before scarce drug substance is committed.

  3. What Established Modalities Can Teach Us About Manufacturing In Vivo CAR-T 10/27/2026

    In vivo CAR-T manufacturing can build on established mRNA-LNP and cell therapy platforms, but requires tailored controls linking formulation attributes, targeted delivery, functional potency, stability, and scalable production.

  4. The mRNA-LNP Decisions That Shape In-Vivo CAR-T Translation 10/27/2026

    Early mRNA-LNP formulation decisions influence in vivo CAR-T delivery, expression, repeat-dose tolerability, stability, scalability, and manufacturing flexibility, shaping therapeutic performance and downstream development risk.

  5. From LNP Delivery To Functional CAR-T: Rethinking Targeting 10/16/2026

    Optimizing LNPs for in vivo CAR-T requires aligning target selection, formulation design, and delivery performance to achieve functional CAR expression in desired T-cell populations while balancing specificity, safety, dosing flexibility, and manufacturability.

  6. The Checklist For Evaluating In-Vivo CAR-T Manufacturing Partners 10/16/2026

    Choosing the right in vivo CAR-T manufacturing partner requires looking beyond cost to the capabilities that protect scalability, compliance, safety, and development timelines.

  7. High-Yield MSC Expansion At The Forefront Of Cell Therapy Advancement 10/14/2026

    As MSC therapies move from autologous to allogeneic use and higher cell doses, the question shifts from efficacy to reliable expansion. See how design, closed handling, and media shape scale-up.

  8. All You Need To Know About GMP Manufacturing Of mRNA-LNP Drug Products 10/13/2026

    Moving mRNA-LNP production from lab to GMP scale exposes tensions among formulation consistency, regulatory expectations, and facility safety, while automation offers ways to resolve them.

  9. Top 5 Things To Know About The Lipid Nanoparticle Portfolio 10/13/2026

    Lipids that shift charge with pH can be chosen to fit the application and delivery route. Varied pKa and biodegradability give developers room to match each therapeutic target.

  10. Expand mRNA-LNP Nanomedicine Potential By Optimizing Lipids 10/13/2026

    Ionizable lipid selection ratios shape how well lipid nanoparticles deliver nucleic acids, and empirical testing shows that similar physical properties can still produce very different performance.